This suggests that passive immunization with tau antibodies is usually a viable therapeutic target and that the CSF volume of p-tau262/356 or of the microtubule binding area (MTBD) can function a beneficial biomarker of tau pathology to watch tau therapeutics in clinical trials.Immerse on your own in TAU’s Daring and emotionally charged performs,